Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Novo | Mind Blowing Facts

Inside Brazil's Judicial Civil War: Three Supreme Court Justices Overrule Each Other Over Federal Police Chief

Brazil's Supreme Court freezes the appointment of top police chief Rolando Alexandre de Souza following conflicting judicial rulings and a $25M contract scandal.

'Game-changer' GLP-1s could fix America's obesity crisis—but 2 inequalities stand in the way

'Game-changer' GLP-1s could fix America's obesity crisis—but 2 inequalities stand in the way

Wells Fargo Industry Insights' Robin Wenzel says the drugs are rewriting healthcare economics, but the math doesn't "pencil out" too often.

Eli Lilly’s Foundayo becomes first oral weight-loss drug approved in UK for diabetes

Eli Lilly’s Foundayo becomes first oral weight-loss drug approved in UK for diabetes

Britain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the UK. Foundayo will launch privately later this month via prescription. Novo Nordisk's Wegovy pill also received approval for the UK market. The weight-loss drug market is seeing increased…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipeline

Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline after recent trial setbacks. The company raised its 2026 sales and profit outlook, but shares fell as investors focused on weaker-than-expected Wegovy pill sales and another setback for obesity…

The Economic Times

Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads

Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers about treatment comparisons. Lilly denies wrongdoing and stands by its advertising claims. Both companies compete in the growing obesity and diabetes drug market. Novo Nordisk argues Lilly uses outdated…

The Economic Times

Novo Nordisk Says Eli Lilly Used Misleading Weight Loss Drug Advertising. It's Suing

The lawsuit, filed Tuesday, alleges that Eli Lilly violated federal and state false advertising laws by promoting "knowingly outdated clinical trial" results that compare both companies' drugs.

International Business Times

Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drug

Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo claims Lilly compared lower doses of its drugs with higher doses of Lilly's. Lilly's advertisements allegedly omit newer, higher-dose versions of Novo's medicines. Novo seeks to withdraw…

The Economic Times

inkl

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer

Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer

India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee recommendation for adults with moderate to advanced liver fibrosis. Wegovy, containing semaglutide, was previously approved for chronic weight management. This marks a significant expansion…

The Economic Times

UK approves Novo weight-loss pill to edge open European market

UK approves Novo weight-loss pill to edge open European market

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatment. Over 10 million people with obesity in the UK now have an alternative to injections. Drugmakers are racing to expand use of these transformative medicines. The market is expected…

The Economic Times

Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage

Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

Novo Nordisk uses AI to fast-track drug launches, expand India role

Novo Nordisk uses AI to fast-track drug launches, expand India role

Novo Nordisk is leveraging Artificial Intelligence to significantly speed up new drug launches. The company expects to cut down the time to market by as much as two-thirds. Its center in Bengaluru, India, is becoming crucial for global drug preparations.

The Economic Times

The Silver Lining of Last Week's Hims & Hers Earnings Miss

The Silver Lining of Last Week's Hims & Hers Earnings Miss

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

Singapore Court of Appeal Notes No Finding of Fraud Against KBP or Dr. Huang; Dispute with Novo Nordisk Undergoing Arbitration Proceedings

SINGAPORE, May 21, 2026 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company" or "KBP") today issued a statement addressing the decision by the Singapore Court of Appeal to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua ("Dr. Huang"), pending final resolution of the arbitration proceedings…

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

CEOs are getting ruthless about worker performance

Corporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volume growth, positive mix, consistent growth margin expansion." This shift towards "performance cultures" involves tougher accountability, potential layoffs, and a focus on tangible outcomes, signaling a departure from the more empathetic approach of the…

Novo Nordisk A/S Q1 Earnings Call Highlights

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi

The Economic Times

Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The campaign aimed to reframe obesity as a chronic disease. It featured various media without naming specific products. Lilly cited regulatory uncertainty and conflicting guidance. The regulator's advisory prohibited indirect promotion…

The Economic Times

Mark Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy

Last October, Novo Nordisk had shut down its cell therapy unit as part of a broader restructuring, discontinuing development ‌of ⁠the therapy.

Get all your
news in one place.

100's of premium titles.
One news app.

What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

The Independent UK

Novo Nordisk shares soar as sales of Wegovy weight loss pill smash forecasts

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly

Evening Standard

Wegovy maker Novo Nordisk boosted by successful weight loss pill launch

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.

Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means

Amazon is stepping into the GLP-1 arena, with the consumer giant positioning itself as a competitor to Hims & Hers Health. Hims may have a problem on its hands.

Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals?

Nuclear, pharma, and travel giants just made significant buyback announcements. However, not all of these are as confidence-inspiring as they may seem.

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand

Eli Lilly is launching Employer Connect to expand Zepbound access while its oral GLP-1 orforglipron just topped Novo Nordisk's Rybelsus in a head-to-head trial.

1 2 3 4 5

People

Mark Zuckerberg

Alexandre de Moraes

Philipp Navratil

Fernando Fernandez

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Court of Appeal

the Court of Appeal

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

153,619 stories

Places

415,787 stories

148,710 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play